Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IB Study of Atezolizumab and Bevacizumab With SBRT for Unresectable Hepatocellular Carcinoma

NCT05096715 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT05096715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05096715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IB Study of Atezolizumab and Bevacizumab With SBRT for Unresectable Hepatocellular Carcinoma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
August 23, 2022
Completion date
January 31, 2032
Enrollment
20 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma